Evidence map›Paper›PMID 36446884›Full record

ArticleBritish journal of cancer2023

Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival.

Kristin Roseth Aass, Tonje Marie Vikene Nedal, Siri Anshushaug Bouma, Synne Stokke Tryggestad, Einar Haukås, Tobias Schmidt Slørdahl, Anders Waage, Therese Standal, Robin Mjelle

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kristin Roseth AassCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Tonje Marie Vikene NedalCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Siri Anshushaug BoumaDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Synne Stokke TryggestadCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Einar HaukåsDepartment of Hematology, Stavanger University Hospital, 4011, Stavanger, Norway.
Tobias Schmidt SlørdahlDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.ORCID http://orcid.org/0000-0001-7488-4863
Anders WaageDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.ORCID http://orcid.org/0000-0001-9072-1220
Therese StandalCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway. therese.standal@ntnu.no.ORCID http://orcid.org/0000-0003-3314-8522
Robin MjelleDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway. robin.mjelle@ntnu.no.ORCID http://orcid.org/0000-0003-3509-4134
Norwegian University of Science and Technology · NOStavanger University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmall RNAs (sRNAs), a heterogenous group of non-coding RNAs, are emerging as promising molecules for cancer patient risk stratification and as players in tumour pathogenesis. Here, we have studied microRNAs (miRNAs) and other sRNAs in relation to survival and disease severity in multiple myeloma.

methodsWe comprehensively characterised sRNA expression in multiple myeloma patients by performing sRNA-sequencing on myeloma cells isolated from bone marrow aspirates of 86 myeloma patients. The sRNA expression profiles were correlated with the patients' clinical data to investigate associations with survival and disease subgroups, by using cox proportional hazards (coxph) -models and limma-voom, respectively. A publicly available sRNA dataset was used as external validation (n = 151).

resultsWe show that multiple miRNAs are differentially expressed between ISS Stage I and III. Interestingly, we observed the downregulation of seven different U2 spliceosomal RNAs, a type of small nuclear RNAs in severe disease stages. Further, by a discovery-based approach, we identified miRNA miR-105-5p as a predictor of poor overall survival (OS) in multiple myeloma. Multivariate analysis showed that miR-105-5p predict OS independently of established disease markers.

conclusionsOverexpression of miR-105-5p in myeloma cells correlates with reduced OS, potentially improving prognostic risk stratification in multiple myeloma.

Indexed as

MicroRNAsMultiple MyelomaBiomarkers, TumorGene Expression Regulation, NeoplasticHumansPrognosisProportional Hazards ModelsBiomarkers, TumorMicroRNAsMIRN105 microRNA, human

Identifiers

PMID36446884
PMCPMC9938247
OpenAlexW4310457692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.